SDY vs XBI
SPDR S&P Dividend ETF vs SPDR S&P Biotech ETF
- • SDY pays a higher dividend yield (2.46%).
Side-by-side metrics
| Metric | SDY | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.35% | 0.35% |
Dividend yield Trailing 12-month yield. | 2.46% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $21.98B | $8.30B |
YTD return | 7.81% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.65 | 1.09 |
P/E ratio | 20.26 | — |
Last price | $148.41 | $133.66 |
Inception | — | — |
Issuer | State Street | State Street |
SDY top holdings
| VZ | Verizon Communications Inc | 3.44% |
| O | Realty Income Corp | 2.48% |
| TGT | Target Corp | 2.37% |
| CVX | Chevron Corp | 2.16% |
| TXN | Texas Instruments Inc | 1.96% |
| PEP | PepsiCo Inc | 1.77% |
| XOM | Exxon Mobil Corp | 1.64% |
| WEC | WEC Energy Group Inc | 1.61% |
| KVUE | Kenvue Inc | 1.55% |
| KMB | Kimberly-Clark Corp | 1.53% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About SDY
SDY (SPDR S&P Dividend ETF) is Highest-yielding S&P Composite 1500 dividend growers. Managed by State Street, the fund carries $22.0B in assets under management, an expense ratio of 0.35%, a dividend yield of 2.46%. Its largest holding is Verizon Communications Inc (VZ), which represents 3.4% of the portfolio. Real Estate is the fund's largest sector exposure at 4.6%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.